Nykredit A S Invests $10.11 Million in Illumina, Inc. $ILMN

Key Points

• Nykredit A/S purchased 57,473 Illumina shares worth approximately $10.11 million in the second quarter. Institutional investors own 89.42% of the company, with BlackRock also establishing a multibillion-dollar position.
• Illumina insiders sold substantial amounts of stock recently, including director Keith Meister’s $26.1 million sale; insiders sold about $436.6 million worth of shares over the past 90 days.
• Illumina reported quarterly EPS of $1.31 and revenue of $1.16 billion, exceeding estimates, while shares opened at $239.62 near their 52-week high. Analyst sentiment is mixed, with a consensus “Hold” rating and average price target of $199.12.

Nykredit A S purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 57,473 shares of the life sciences company's stock, valued at approximately $10,105,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Illumina during the 2nd quarter worth about $3,374,423,000. Plato Investment Management Ltd bought a new stake in shares of Illumina in the 2nd quarter valued at about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $30,501,000. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $129,792,000. Finally, Impact Partnership Wealth LLC boosted its stake in Illumina by 235.8% during the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company's stock worth $1,366,000 after acquiring an additional 7,780 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares of the company's stock, valued at $168,244,440. The trade was a 13.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,062,465 shares of company stock valued at $436,589,802 in the last ninety days. Insiders own 2.90% of the company's stock.

Illumina Price Performance

NASDAQ:ILMN opened at $239.62 on Monday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a fifty day simple moving average of $204.62 and a 200 day simple moving average of $166.03. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $250.06. The stock has a market capitalization of $36.18 billion, a PE ratio of 44.71, a P/E/G ratio of 3.40 and a beta of 1.46.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm posted $1.19 EPS. The company's quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analyst Ratings Changes

ILMN has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a "buy" rating in a report on Friday, July 31st. Piper Sandler restated an "overweight" rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. JPMorgan Chase & Co. upped their price objective on Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Argus increased their price objective on Illumina from $180.00 to $235.00 and gave the stock a "buy" rating in a report on Thursday, September 3rd. Finally, Royal Bank Of Canada lifted their target price on Illumina from $170.00 to $230.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $199.12.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company's sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.